Otorhinolaryngological manifestations of COVID-19-A systematic review

DOI: https://doi.org/10.21203/rs.3.rs-83423/v1

Abstract

Background: In early December 2019, an outbreak of COVID-19, caused by a novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), occurred in Wuhan City, Hubei Province, China causing havoc all over the world. As clinicians, recognition of this disease is necessary to isolate these patients to prevent further human to human transmission. Due to its affinity to the respiratory tract and increased viral load in the nose and throat, we as practising otorhinolaryngologists are at increased risk of exposure to this life-threatening virus and warrants an in-depth knowledge on the symptomatology of this disease. This systematic review is intended to highlight the otorhinolaryngological manifestations of COVID-19.

Methodology: The literature search was performed on PubMed database using Boolean operators ‘and ‘, ‘or’ as “otorhinolaryngological manifestations” or “rhinology” or “otology” or “larynx” or “hearing” or “olfaction” and “covid19” or “novel corona virus” or “SARS-CoV” with filters as ‘2020’ year of study on 7/08/2020 at 11.30 Am.

Review Results: Total of 357 articles were obtained on search and the final 12 articles extracted based on our selection criteria were reviewed. The studies included 6825 laboratory confirmed COVID -19 patients with varying severity of disease. Olfactory dysfunction and taste dysfunction were noted in 2355 and 2224 patients respectively. Nasal obstruction was reported in 323 patients and sore throat in 261 patients. Rhinorrhoea was reported in 209 patients .158 patients complained of post nasal drip and 152 patients presented with facial pain.

Conclusion: As a practising otorhinolaryngologist, a good insight into the otorhinolaryngological manifestations of COVID-19 is essential to differentiate between the prodromal symptoms of COVID-19 and non-COVID viral upper respiratory tract infection.

Background

Coronaviruses are enveloped positive stranded RNA viruses belonging to the family Coronaviridae and the order Nidovirales, with spikes on its surface giving it a crown like ultrastructural appearance; hence was named coronavirus. The 2019 novel coronavirus (2019-nCoV) or the severe acute respiratory syndrome corona virus 2 (SARS-CoV-2) as it is now called, has swiftly spread from its origin in Wuhan City of China to all around the globe. As on 14/09/2020 there has been 29 million cases with reported deaths around 9,25,000 worldwide. India ranks second in the case burden with 4.85 million cases and 79,722 deaths till then.

The incubation period for COVID-19 is believed to reach 14 days, nevertheless, most of the patients develop symptoms of COVID-19 disease after 4–5 days post infection. COVID-19 remains contagious even during the incubation period, thus patients before clinical COVID-19 presentation can spread the virus to others. Infection with 2019-nCoV presents with non-specific features such as malaise, fever, and dry cough at the prodromal phase. Symptoms of COVID-19 ranges from no symptoms, mild upper respiratory tract infection to very severe lower respiratory tract infection with bilateral lung infiltrates. Despite respiratory symptoms, COVID-19 presents with a plethora of other systemic features.

Due to its affinity to the respiratory tract, we as practising otorhinolaryngologists are at increased risk of exposure to this life-threatening virus and demands an in-depth knowledge on the symptomatology of this disease. This systematic review is intended to highlight the otorhinolaryngological manifestations of COVID-19.

Methodology

Search strategy and selection criteria: The literature search was performed on PubMed database using Boolean operators ‘and ‘, ‘or’ as “otorhinolaryngological manifestations” or “rhinology” or “otology” or “larynx” or “hearing” or “olfaction” and “covid19” or “novel corona virus” or “SARS-CoV” with filters as ‘2020’ year of study. There were no restrictions on the language of articles published. After eliminating duplicates, three investigators independently reviewed all article title: the full texts of articles considered as eligible for review were extracted for further analysis. Thereafter, eligible articles were selected for final analysis according to predefined inclusion and exclusion criteria. Difference of opinion between the authors were solved by consensus. We included only human studies and articles with clearly defined clinical outcome. The exclusion criteria included animal studies, single case reports and review articles. The search was performed at specified date and time on 7/08/2020 at 11.30 Am.

Results

Total of 357 studies were obtained on PubMed database search, out of which 329 studies were excluded after checking the relevance of title. Full text article of the remaining 28 articles were read thoroughly and 16 out of them were excluded due to various reasons (two studies were guidelines for otorhinolaryngological practice, seven studies were review articles,2 were related to anosmia in COVID era in patients not confirmed with COVID infection, one study was on recovery of anosmia post-COVID, three studies were case reports and one another study was on the pathophysiology of anosmia in COVID).Search was done strictly adhering to the PRISMA guidelines, as depicted in Chart 1.

We reviewed the final 12 articles based on our selection criteria to extract the following information from each: first author, study design, number of patients, demographic data of study population, otorhinolaryngological manifestations of COVID 19 and drawbacks of study if any. The studies included for this review collectively included 6825 laboratory confirmed COVID -19 patients with varying severity of disease. The extracted data is jotted in Table 1.

4123 females and 2647 males were included (gender distribution was not elaborated in two studies). Olfactory dysfunction and taste dysfunction was noted in 2355 and 2224 patients respectively. In the studies performed by Lauren T Roland et al4 and Antje Haehner et al9 Anosmia or ageusia were reported in 95 and 22 patients respectively. Nasal obstruction was reported in 323 patients followed by next common symptom sore throat in 261 patients. Rhinorrhoea was reported in 209 patients .158 patients complained of post nasal drip and 152 patients presented with facial pain. Dysphagia was reported by 42 patients and 61 patients had ear pain. Mucus production was one of the presenting symptoms in 36 patients. Table 2.

Discussion

In most of the studies included in our review females were most commonly affected than males. Most of the available literature suggest a contrary observation indicating males have more susceptibility that females due to the fact that there are many differences between men and women in the immune response to Covid-19 infection. Women, compared to men, are less prone to viral infections based on a different innate immunity, steroid hormones and factors related to sex chromosomes. The presence of two X chromosomes in women emphasizes the immune system even if one is inactive. The immune regulatory genes encoded by X chromosome in female gender causes lower viral load levels, and less inflammation than in man, while CD4+ T cells are higher with better immune response. In addition, women generally produce higher levels of antibodies which remain in the circulation longer.13

COVID-19 and its relation with olfactory and gustatory dysfunction is a well-known fact and there have been abundant literature on the same. Olfactory and gustatory dysfunction are more prevalent in patients with mild to moderate disease probably due to the fact that in patients with severe disease these symptoms are commonly overlooked and less reported. In our review we noted that anosmia and ageusia are the most common otorhinolaryngological manifestation of COVID-19.

Due to the affinity of coronavirus towards upper respiratory mucosa, nasal obstruction seems to be a common symptom next only to anosmia and ageusia. Rhinorrhoea and sore throat are common observations in patients with COVID-19 infection. The prodromal symptoms of COVID 19 infection and non COVID Upper respiratory viral infection include nasal obstruction and sore throat, therefore differentiating between both becomes a challenging task. Hence at our institution we have a flu OPD (with necessary safety precautions), where patients with URI and Pharyngitis (sore throat) undergo thermal screening, vitals assessment, Chest X ray and rapid antigen testing to rule out COVID-19 infection. After ruling out COVID-19 infection patient is referred to Otorhinolaryngologist for definitive management. This practise ensures safety at workplace for Otorhinolaryngologist in routine OPD and similar practise is recommended by the authors.

Facial pain and post nasal drip were recorded in 152 and 158 patients respectively, in the study performed by Jerome R. Lechien et al2 indicating that sinusitis frequently occurs in concordance with COVID-19 infection, other studies included in our review did not indicate such association. This indicates that there is a lacuna in literature regarding the incidence of sinusitis in COVID-19 patients. Sneezing was not reported in any of the included study.

Otological symptoms seems to be less common in COVID-19 patients. In the study performed by Jerome R. Lechien et al2 ear pain was documented in 61 patients. In the study performed by Mustafa et al7, they observed that the high frequency pure-tone thresholds as well as the TEOAE amplitudes were significantly worse in the test group. The results of their study showed that COVID-19 infection had deleterious effects on the hair cell of cochlea. The drawback of this particular study is the small cohort. In a case reported by Osman Kilic et al14 they noted sudden sensorineural hearing loss in a 29-year-old patient. Studies on large population is required to confirm the deleterious effect of COVID-19 infection on the hair cells of cochlea.

Conclusion

As a practising otorhinolaryngologist, a good insight into the otorhinolaryngological manifestations of COVID-19 is essential to differentiate between the prodromal symptoms of COVID-19 and non-COVID viral upper respiratory tract infection. Patients of COVID-19 tend to frequently present with anosmia and ageusia which is common in mild to moderately severe disease. Despite this, frequently they present with nasal obstruction, sore throat, rhinorrhoea, postnasal drip, facial pain, nasal congestion and ear pain in decreasing order of frequency.

References

  1. Lee Y, Min P, Lee S, Kim SW. Prevalence and duration of acute loss of smell or taste in COVID-19 patients. Journal of Korean medical science. 2020 May 11;35(18).
  2. Lechien JR, Chiesa-Estomba CM, De Siati DR, Horoi M, Le Bon SD, Rodriguez A, Dequanter D, Blecic S, El Afia F, Distinguin L, Chekkoury-Idrissi Y. Olfactory and gustatory dysfunctions as a clinical presentation of mild-to-moderate forms of the coronavirus disease (COVID-19): a multicenter European study. European Archives of Oto-Rhino-Laryngology. 2020 Apr 6:1-1.
  3. Yan CH, Faraji F, Prajapati DP, Boone CE, DeConde AS. Association of chemosensory dysfunction and Covid‐19 in patients presenting with influenza‐like symptoms. InInternational forum of allergy & rhinology 2020 Apr 12.
  4. Roland LT, Gurrola JG, Loftus PA, Cheung SW, Chang JL. Smell and taste symptom‐based predictive model for COVID‐19 diagnosis. InInternational Forum of Allergy & Rhinology 2020 May 4.
  5. Yan CH, Faraji F, Prajapati DP, Ostrander BT, DeConde AS. Self‐reported olfactory loss associates with outpatient clinical course in COVID‐19. InInternational Forum of Allergy & Rhinology 2020 Apr 24.
  6. Dell’Era V, Farri F, Garzaro G, Gatto M, Aluffi Valletti P, Garzaro M. Smell and taste disorders during COVID‐19 outbreak: A cross‐sectional study on 355 patients. Head & Neck. 2020 Jun 11.
  7. Mustafa MW. Audiological profile of asymptomatic Covid-19 PCR-positive cases. American Journal of Otolaryngology. 2020 Apr 10:102483.
  8. Speth MM, Singer-Cornelius T, Obere M, Gengler I, Brockmeier SJ, Sedaghat AR. Olfactory Dysfunction and Sinonasal Symptomatology in COVID-19: Prevalence, Severity, Timing, and Associated Characteristics. Otolaryngology--Head and Neck Surgery. 2020 May 19.
  9. Haehner A, Draf J, Draeger S, Hummel T. Predictive value of sudden olfactory loss in the diagnosis of COVID-19. ORL. 2020 May 3:1-6.
  10. Sierpiński R, Pinkas J, Jankowski M, Zgliczyński WS, Wierzba W, Gujski M, Szumowski Ł. Gender differences in the frequency of gastrointestinal symptoms and olfactory or taste disorders among 1,942 non-hospitalized patients with COVID-19. Polish Archives of Internal Medicine. 2020 Jun 3.
  11. Lechien JR, Cabaraux P, Chiesa‐Estomba CM, Khalife M, Hans S, Calvo‐Henriquez C, Martiny D, Journe F, Sowerby L, Saussez S. Objective olfactory evaluation of self‐reported loss of smell in a case series of 86 COVID‐19 patients. Head & Neck. 2020 May 21.
  12. Vaira LA, Hopkins C, Salzano G, Petrocelli M, Melis A, Cucurullo M, Ferrari M, Gagliardini L, Pipolo C, Deiana G, Fiore V. Olfactory and gustatory function impairment in COVID‐19 patients: Italian objective multicenter‐study. Head & Neck. 2020 May 21.
  13. Conti P, Younes A. Coronavirus COV-19/SARS-CoV-2 affects women less than men: clinical response to viral infection. J Biol Regul Homeost Agents. 2020 Apr 7;34(2):71.
  14. Kılıc O, Kalcıoglu MT, Cag Y, Tuysuz O, Pektas E, Caskurlu H, Cetın F. Could sudden sensorineural hearing loss be the sole manifestation of COVID-19? An investigation into SARS-COV-2 in the etiology of sudden sensorineural hearing loss. International Journal of Infectious Diseases. 2020 Jun 12.

Tables

Table 1:Comprehensive data obtained from the studies included

SR.NO

FIRST AUTHOR

STUDY DESIGN

STUDY POPULATION

NUMBER OF PATIENTS

AGE

GENDER

OTORHINOLARYNGOLOGICAL MANIFESTATIONS

DRAWBACKS OF STUDY

1

Yonghyun Lee et al1

Prospective

Korean

3191

36.5 years(24.5–54)

 

Females2030(68.9%)

Males1161(31.1%)

Anosmia and aguesia254(8%)

Anosmia only 135(4.2%)

Aguesia only 99(3.1)

Study included only asymptomatic-to-mild disease severity. The study was entirely on anosmia and ageusia.

2

Jerome R. Lechien et al2

Prospective

European

417

36.9±11.4 years ( 19–77)

Females 263 (63.1%)

Males 154(36.9%)

Out of 417, patients 357 (85.6%) olfactory dysfunction. 284 (79.6%) patients were anosmic, 73 (20.4%) were hyposmic, phantosmia(12.6%) and parosmia(32.4%).

Out of 417 patients ,342 patients (88.8%) reported gustatory disorders, reduced /discontinued (78.9%) or distorted ability (21.1%) to taste flavors.

Nasal obstruction 194(46.5%), Rhinorrhea139(33.3%), Postnasal drip116(27.8%), Sore throat 128(30.7%),Face pain/heaviness 152(36.5%), Ear pain 61(14.6%),Dysphagia 42(10.1%), Dyspnea 115(27.6%)

Study included mild-to-moderate COVID-19 patients of age group >18yrs.

The otorhinolaryngological symptoms were graded on the basis of relatedness to COVID infection. In the data presented here the patients who had otorhinolaryngological symptoms not related to COVID infection are not included.

3

Carol H. Yan et al3

cross-sectional stdy

Americans

59

18-79 Years

Females 29(49.2%)

Males 29 (49.2%)

Transgender 1(1.6%)

Ageusia 42 (71%), Anosmia 40(68%)

Nasal obstruction 28(47.5%), sore throat 19(32.2%), Rhinorrhea 18(30.5%)

 

Short sampling period at a single institution, as well as the subjective assessment used to determine smell/taste impairment. Furthermore, by surveying respondents after Covid-19-testing, risk of post-hoc interpretations of smell and taste loss through their knowledge of their diagnosis, a potential recall bias especially in the context of pervasive anecdotal reports of Covid-19-related anosmia cannot be ruled out

 

4

Lauren T. Roland et al4

cross-sectional study

Americans

145

40+13 years

Females 94(64.8%)  Males 51(35.2%)

Change in smell/taste 95(66%),sore throat 59(41%),nasal congestion 68(47%), Rhinorrhoea 52(36%),Dyspnoea 50(34%)

Study included patients older than 18 years and was questionnaire based(risk of post-hoc interpretations of smell and taste loss through their knowledge of their diagnosis cannot be ruled out).

5

Carol H. Yan et al5

Retrospective study

Americans

128(26 admitted and 102 ambulatory)

53.5 years (40-65) admitted

43 years (34-54) ambulatory

Admitted patients

Females 17(65.4%)

Males 9(34.6%)

Ambulatory patients

Females 50(49%)

Males 52(51%)

Anosmia/hyposmia 7(26.9%)admitted vs 68 (66.7%)ambulatory and dysgeusia 6(23.1%)admitted vs 64(62.7%)ambulatory

Sore throat 9(34.6%) admitted vs 46(45.1%)ambulatory

 

Focuses on mild to moderate Covid-19 patients. Prospective studies are required to better determine the extent to which anosmia informs overall disease trajectory

6

Valeria Dell’Era et al6

cross-sectional study

Italians

355

Olfactory symptoms 49 years (40-60)

Taste symptoms 51 years (51-60)

 

Females 163(45.9%)

Males 192(54.1)

Olfactory dysfunction

Females 115(48.5%) Males 122(51.5%)

Taste Dysfunction

Females 122(52.6%)

Males 110(47.4%)

 

Olfactory symptoms 234(66%), taste disorders 232(65.4%)

 

The olfactory and gustatory assessment were subjective and was not proved by endoscopy/imaging /specific assessments sone over a short period in a single center.

7

Mustafa et al7

Prospective study

Egypt

20

20-50 years

 

The high frequency pure-tone thresholds as well as the TEOAE amplitudes were significantly worse in the test group. The results of the current study showed that COVID-19 infection had deleterious effects on the hair cell of cochlea

Study was performed on a small cohort of COVID positive asymptomatic patients.

8

Marlene M. Speth et al8

Prospective, cross-sectional

Americans

103

46.8 ± 15.9 years

Females 53(51.5%)

Males 50(48.5%)

Olfactory Dysfunction 63( 61.2%), gustatory dysfunction 67(65%), nasal obstruction 51(49.5%), mucus production 36(35%).

Studied subjective reports in select patient due to present logistical constraints related to meeting with infected patients to apply objective olfactory testing

9

Antje Haehner et al9

Prospective, cross-sectional

German

34

 

 

Sudden smell and taste loss 22(64.7%)

URTI patient cohort study of a coronavirus testing center out of which 32% were positive(Demographic details and symptoms  of COVID patients are not described specifically)

10

Radoslaw sierpinski et al10

Cross sectional survey

Poland

1942

50 years

Females 1169(60.2%)

Males 773(39.8%)

Olfactory disorder 956(49.2%)

Taste disorder 923(47.5%)

Questionnaire based (risk of post-hoc interpretations of smell and taste loss through their knowledge of their diagnosis cannot be ruled out)

11

Jerome R. Lechien et al11

Prospective

Europeans

86

41.7 ± 11.8 years

Females 56 (65.1%)

Males 30 (34.9%)

Nasal obstruction50 (58.6%), postnasal drip 42(48.6%), dysgeusia 40(47.1%)

Self-reported and questionnaire based (risk of post-hoc interpretations of smell and taste loss through their knowledge of their diagnosis cannot be ruled out)

12

Luigi Angelo Vaira et al12

Prospective

Italians

345

48.5 ± 12.8 years (23-88)

Females 199 (57.7%)

Males 146 (42.3%)

Olfactory function

Normal 104(30.1%) Mild hyposmia 76(22%) Moderate hyposmia 59(17.1%) Severe hyposmia 45(13%) Anosmia 61(17.7%)

Gustatory function

Normal 190(55.1%) Mild hypogeusia 78 (22.6%)

Moderate hypogeusia25 (7.2%), Severe hypogeusia 16 (4.6%)Ageusia 36 (10.4%)

Part of the cohort self-reported the symptoms and part of them were hospitalised, hence recorded by trained personnel.

 

Table 2: Number of patients with various otorhinolaryngological symptoms from the included studies.

 

Sr.No

First Author

Total number of patients

Males

Females

Olfactory dysfunction

Taste Dysfunction

Nasal obstruction

Rhinorrhea

Sore throat

Nasal congestion

Mucus production

Facial pain

PND

Sneezing

Ear pain

Dysphagia

1

Yonghyun Lee et al1

3191

1161

2030

389

353

-

-

-

-

-

-

-

-

-

-

2

Jerome R. Lechien et al2

417

154

263

357

342

194

139

128

-

-

152

116

-

61

42

3

Carol H. Yan et al3

59

29

29

40

42

28

18

19

-

-

-

-

-

-

-

4

Lauren T. Roland et al4

145

51

94

Anosmia/Ageusia 95

-

52

59

68

-

-

-

-

-

-

5

Carol H. Yan et al5

128

61

67

75

70

-

-

55

-

-

-

 

-

-

-

6

Valeria Dell’Era et al6

355

192

163

234

232

-

-

-

-

-

-

-

-

-

-

7

Mustafa et al7

20

 

 

-

-

-

-

-

-

-

-

-

-

-

-

8

Marlene M. Speth et al8

103

50

53

63

67

51

-

-

-

36

-

-

-

-

-

9

Antje Haehner et al9

34

 

 

Anosmia/Ageusia 22

-

-

-

-

-

-

-

-

-

-

10

Radoslaw sierpinski et al10

1942

773

1169

956

923

-

-

-

-

-

-

-

-

-

-

11

Jerome R. Lechien et al11

86

30

56

-

40

50

-

-

-

-

-

42

-

-

-

12

Luigi Angelo Vaira et al12

345

146

199

241

155

-

-

-

-

-

-

-

-

-

-

Total

 

6825

2647

4123

2355

2224

323

209

261

68

36

152

158

0

61

42